TRAVOTAK (Travoprost Ophthalmic Solution IP) is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes. Treats high pressure inside the eye including glaucoma. It has a role as an anti-glaucoma drug, an antihypertensive agent, a prodrug, an ophthalmology drug and a prostaglandin receptor agonist.
Specifically it is used for open angle glaucoma when other agents are not sufficient.
TRAVOTAK (Travoprost Ophthalmic Solution IP) is a synthetic lipophilic isopropyl ester prodrug of the active compound travoprost free acid, a prostaglandin F2alpha analog with anti-glaucoma property. Upon administration, travoprost is hydrolysed to a free acid by corneal esterases, and then selectively stimulating the prostaglandin F (FP prostanoid) receptor, thereby increasing the uveoscleral outflow which leads to a reduction in intra-ocular pressure.
TRAVOTAK (Travoprost Ophthalmic Solution IP), a prostaglandin F2α analogue, is a highly selective full agonist which has a high affinity for the prostaglandin FP receptor, and facilitates reductions in intraocular pressure by increasing the outflow of aqueous humour via trabecular meshwork and uveoscleral pathways.
- Effects generally occur within two hours and maximum effect is reached after 12 hours.
- Travoprost is absorbed through the cornea, where it is hydrolysed to the free travoprost acid.
- Highest concentrations of the acid in the eye are reached one to two hours after application, and its half-life in the aqueous fluid is 1.5 hours
- Travoprost acid and its metabolites are mainly excreted via the kidney. with a terminal half-life of 45 minutes
- A well-received therapeutic agent with demonstrated efficacy and safety
- Significant lowering of intraocular pressure can be maintained for periods exceeding 24 hours with a single dose.
- Travoprost appears to lower IOP by facilitating aqueous outflow through both the uveoscleral outflow pathway and the trabecular outflow pathway
- Travoprost treatment leads to SC lumen expansion
